Kyle Rose

Zimmer Biomet Holdings Inc (NYSE: ZBH) seems to be on the verge of beginning a multiyear cycle of accelerating top-line growth, according to Canaccord Genuity. The Analyst Canaccord Genuity’s Kyle Rose upgraded Zimmer Biomet from Hold to Buy, while raising the price target from $137 to $167....

Medical technology and orthopedic implant company Stryker Corporation (NYSE: SYK) reported an earnings beat Tuesday, and three sell-side analysts remain bullish on the stock. Stryker reported quarterly earnings of $1.88 per share, beating the consensus estimate of $1.84 and up about 12...

Despite a more than 35 percent plunge in DexCom, Inc. (NASDAQ: DXCM)'s stock, analysts at Canaccord Genuity continue to hold a bullish outlook. The firm's Kyle Rose maintains a Buy on DexCom's stock with a price target lowered from $90 to $69. DexCom's stock was hard hit on Thursday...

Going by the mixed first-quarter print of NuVasive, Inc. (NASDAQ: NUVA), Canaccord Genuity believes any weakness presents a buying opportunity for the shares of the company. The stock was seen trading down 4.39 percent at $73.56 in reaction to the results. Q1 Review Analyst Kyle Rose noted...